Home
Dashboard
Curated content
Startups & Scaleups
New startups
Jobs
Corporates
Investors
Funding rounds
Exits
Accelerators
Workspaces
Universities
More organizations
Matching tool
Investment heatmap
Themes
News
Companies
Nirvana Life Sciences
Save
Nirvana Life Sciences
Is focused on developing medical.
Market cap
€2.4m
Enterprise valuation
€2m
(Public information from Sep 2024)
Share price
CAD0.075 NIRV.CN
Vancouver British Columbia (HQ)
http://nirvanalifesciences.com
https://www.facebook.com/nirvanalifesciences
https://www.linkedin.com/company/nirvanalifesciencesinc/
B2B
manufacturing
health
biotechnology
hard tech
biotechnology
biotech and pharma
psychedelic drugs
Overview
Similar companies
Analytics
Notes
Job openings
Innovations (0)
Financials
Estimates*
Edit
Revenues, earnings & profits over time
CAD
2020
2021
2022
2023
EBITDA
(<1m)
(<1m)
3.4m
(1.2m)
Profit
(<1m)
(<1m)
(5.7m)
(1.5m)
EV / EBITDA
-
-
1.2x
-0.9x
R&D budget
-
-
<1m
<1m
Nirvana Life Sciences funding
Nirvana Life Sciences investors
Edit
Date
Investors
Amount
Round
Feb 2021
ThreeD Capital
$450k
Early VC
Mar 2022
N/A
N/A
IPO
Jun 2022
*
ThreeD Capital
N/A
Acquisition
Total Funding
€409k
Recent News about Nirvana Life Sciences
Edit